Early vasoactive drugs improve heart failure outcomes

Congestive Heart Failure
W Frank PeacockGregg C Fonarow

Abstract

Vasoactive therapy is often used to treat acute decompensated heart failure (ADHF). The authors sought to determine whether clinical outcomes are temporally associated with time to vasoactive therapy (vasoactive time) in ADHF. Using the Acute Decompensated Heart Failure (ADHERE) Registry, the authors examined the relationship between vasoactive time and inpatient mortality within 48 hours of hospitalization. Vasoactive agents were used early (defined as <6 hours) in 22,788 (63.8%) patients and late in 12,912 (36.2%). Median vasoactive time was 1.7 and 14.7 hours in the early and late groups, respectively. In-hospital mortality was significantly lower in the early group (odds ratio, 0.87; 95% confidence interval, 0.79-0.96; P=.006), and the adjusted odds of death increased 6.8% for every 6 hours of treatment delay (95% confidence interval, 4.2-9.6; P<.0001). Early vasoactive initiation is associated with improved outcomes in patients hospitalized for ADHF.

Associated Clinical Trials

References

Mar 28, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF)
Mar 28, 2002·JAMA : the Journal of the American Medical Association·Michael S CuffeUNKNOWN Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigato
May 22, 2002·Journal of the American College of Cardiology·Wendy JohnsonLynne W Stevenson
Feb 26, 2004·The Annals of Pharmacotherapy·Robert J DiDomenicoGlen T Schumock
Apr 29, 2004·JAMA : the Journal of the American Medical Association·Mihai GheorghiadeUNKNOWN Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators
Feb 3, 2005·JAMA : the Journal of the American Medical Association·Gregg C FonarowUNKNOWN ADHERE Scientific Advisory Committee, Study Group, and Investigators
Apr 6, 2005·Heart Failure Reviews·Gregg C FonarowUNKNOWN ADHERE Scientific Advisory Committee
Jul 13, 2005·Archives of Internal Medicine·Gregg C FonarowUNKNOWN ADHERE Scientific Advisory Committee, Study Group, and Investigators
Oct 4, 2005·The American Journal of Cardiology·Mihai GheorghiadeGary S Francis
Dec 21, 2005·Circulation·Mihai GheorghiadeUNKNOWN International Working Group on Acute Heart Failure Syndromes
Jan 13, 2006·Circulation·Thomas ThomUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee

❮ Previous
Next ❯

Citations

Apr 6, 2011·Cardiology in Review·Carlos E Sanchez, David R Richards
Oct 20, 2011·International Heart Journal·Alan S MaiselRyozo Nagai
Sep 16, 2015·Intensive Care Medicine·A MebazaaJ Januzzi
Jan 15, 2014·The American Journal of Emergency Medicine·Adam J SingerW Frank Peacock
Nov 2, 2011·Emergency Medicine Clinics of North America·Peter S Pang
Jan 15, 2016·Progress in Cardiovascular Diseases·Ruth Hsiao, Barry Greenberg
May 31, 2011·The Journal of Emergency Medicine·Richard RoAdam J Singer
Nov 27, 2014·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·Sean P CollinsDaniel J Lenihan
Sep 13, 2011·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·W Frank PeacockAlan S Maisel
Mar 12, 2015·Pharmacotherapy·Suprat S WilsonPhillip D Levy
Oct 19, 2016·Clinical and Experimental Emergency Medicine·Dick C Kuo, W Frank Peacock
Feb 3, 2016·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·Michael A Kohn, Brian Steinhart
Oct 4, 2016·Annales de cardiologie et d'angéiologie·S AndrieuM Pansieri
Jul 1, 2015·European Heart Journal. Acute Cardiovascular Care·Christian MuellerUNKNOWN Acute Heart Failure Study Group of the ESC Acute Cardiovascular Care Association
Apr 5, 2017·International Journal of Clinical Pharmacy·Jérémy ChambordStéphane Gibaud
Jun 24, 2017·Journal of the American College of Cardiology·Yuya MatsueTakeshi Kitai
Apr 24, 2015·European Heart Journal. Acute Cardiovascular Care·Michael Christ, Christian Mueller
Mar 30, 2018·Circulation Journal : Official Journal of the Japanese Circulation Society·Albert Youngwoo JangJeonggeun Moon
Oct 11, 2017·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·Sean P CollinsJaved Butler
Dec 6, 2017·Intensive Care Medicine·Tahar ChouihedAlexandre Mebazaa
Jun 2, 2018·Korean Circulation Journal·Kamilė ČerlinskaitėUNKNOWN Global Research on Acute Conditions Team (GREAT) Network
Oct 13, 2010·Circulation·Neal L WeintraubUNKNOWN American Heart Association Council on Clinical Cardiology and Council on Cardiopulmonary, Critical Care, Perioperative and R
Nov 16, 2018·Circulation Journal : Official Journal of the Japanese Circulation Society·Toru KondoToyoaki Murohara
Sep 3, 2019·Clinical and Experimental Emergency Medicine·Heba R GaberW Frank Peacock
Nov 9, 2019·ESC Heart Failure·Pia HarjolaUNKNOWN EMS-AHF Study Group
Jul 6, 2019·Journal of Cardiovascular Pharmacology·Aldo BonaventuraAntonio Abbate
Jun 6, 2020·International Journal of Clinical Practice·Imen TrabelsiUNKNOWN GREAT Network
May 28, 2014·Clinical Chemistry and Laboratory Medicine : CCLM·Salvatore Di SommaFrank W Peacock
Feb 15, 2014·Critical Pathways in Cardiology·James F NeuenschwanderWilliam T Abraham
Mar 5, 2019·Current Heart Failure Reports·Anna Marie ChangSean P Collins
Mar 7, 2019·American Journal of Therapeutics·Elena-Laura AntohiOvidiu Chioncel

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.